Attacking the roots of AML
In some cases of AML, people can see their disease return. This is because some cells get left behind despite treatment. Professor Bertie Göttgens wants to understand more about this and find new ways to treat the disease.
All the different types of blood cells in our body come from a specialised cell called a ‘blood stem cell’. In acute myeloid leukaemia (AML), changes can happen in the genes of blood stem cells causing them to turn into ‘pre-leukaemia’ cells. While it is possible to treat AML, around half of people will see their cancer return after their first treatment because the treatment is unable to kill off these pre-leukaemic cells.
Using cutting-edge technology, Professor Göttgens and his team will look at the activity of thousands of genes within a single cell and will see which ones are responsible for turning healthy blood stem cells into pre-leukaemic cells. They will then test whether disrupting these genes can kill off the pre-leukaemic cells.
If successful, this research will lead to a new generation of AML treatments that will be able to target pre-leukaemic stem cells and hopefully prevent the disease from returning.